This company has been acquired
Avadel Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 5.2yrs |
| Board average tenure | no data |
Recent management updates
Recent updates
Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes
Oct 23Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10
A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb
Aug 02Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jun 10
LUMRYZ And REVITALYZ Trials Will Unlock Future Value
LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers.Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher
May 04Avadel Pharmaceuticals: Moving To A Speculative Buy
Feb 11The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%
Feb 07Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jan 13The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
Dec 01Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Nov 22Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
Oct 16Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22CEO
Avadel Pharmaceuticals has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP | 6.2yrs | US$2.29m | 0.089% $ 1.9m | |
| General Counsel | 5.4yrs | US$2.04m | 0.0090% $ 190.3k | |
| Chief Operating Officer | less than a year | no data | no data | |
| VP of Corporate and Business Development | 10.6yrs | no data | 0.17% $ 3.7m | |
| Vice President of People & Culture | 4.8yrs | no data | no data | |
| Senior Vice President of Technical Operations | 6.2yrs | no data | no data | |
| Senior Vice President of Medical & Clinical Affairs | 5.2yrs | no data | no data | |
| Chief Business Officer | 1.8yrs | no data | no data | |
| Senior Vice President of Regulatory & Quality | 1.8yrs | no data | no data |
Experienced Management: AVDL's management team is seasoned and experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/14 07:59 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avadel Pharmaceuticals plc is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Brean Capital Historical (Janney Montgomery) |
| Jason Butler | Citizens JMP Securities, LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |